CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | PC0125-000 |
|---|---|
| Brand Name | Alecensaro |
| Generic Name | Alectinib |
| Strength | 150 mg |
| Tumour Type | Lung |
| Indication | Non-Small Cell Lung Cancer (first line) |
| Funding Request | For the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer |
| Review Status | Complete |
| Pre Noc Submission | Yes |
| NOC Date | June 11, 2018 |
| Manufacturer | Hoffmann-La Roche Limited |
| Sponsor | Hoffmann-La Roche Limited |
| Submission Date | January 15, 2018 |
| Submission Deemed Complete | January 22, 2018 |
| Submission Type | Initial |
| Prioritization Requested | Requested and Granted |
| Stakeholder Input Deadline ‡ | January 29, 2018 |
| Check-point meeting | March 6, 2018 |
| pERC Meeting | June 21, 2018 |
| Initial Recommendation Issued | July 6, 2018 |
| Feedback Deadline ‡ | July 20, 2018 |
| Final Recommendation Issued | July 25, 2018 |
| Notification to Implement Issued | August 10, 2018 |
| Therapeutic Area | Locally advanced or metastatic ALK+ NSCLC (first line) |
| Recommendation Type | Reimburse with clinical criteria and/or conditions |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
